{"id":183796,"date":"2023-07-26T00:00:00","date_gmt":"2023-07-25T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/daclizumab-zinbryta-stand-van-zaken-5-jaar-na-commercialisering-3\/"},"modified":"2023-07-26T00:00:00","modified_gmt":"2023-07-25T22:00:00","slug":"daclizumab-zinbryta-stand-van-zaken-5-jaar-na-commercialisering-3","status":"publish","type":"post","link":"https:\/\/cbip.be\/fr\/daclizumab-zinbryta-stand-van-zaken-5-jaar-na-commercialisering-3\/","title":{"rendered":"Daclizumab (Zinbryta\u00ae): stand van zaken 5 jaar na commercialisering"},"content":{"rendered":"<div class=&quot;summary&quot;>Daclizumab (Zinbryta\u00ae) werd 5 jaar geleden gecommercialiseerd met als indicatie de behandeling van <i>relapsing-remitting<\/i> multiple sclerose. Deze IL-2 receptor antagonist werd in 2018 door de firma van de markt gehaald nadat het Europees geneesmiddelenagentschap een <a href=&quot;https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-immediate-suspension-recall-multiple-sclerosis-medicine-zinbryta&quot;>dringende evaluatie<\/a> had opgestart omwille van een risico van encefalitis en meningo-encefalitis.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Daclizumab (Zinbryta\u00ae) werd 5 jaar geleden gecommercialiseerd met als indicatie  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,14914],"tags":[20213],"class_list":["post-183796","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2023-fr","tag-import_tags"],"_links":{"self":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts\/183796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=183796"}],"version-history":[{"count":0,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/posts\/183796\/revisions"}],"wp:attachment":[{"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=183796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=183796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=183796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}